Exelixis PI3K Inhibitor XL147 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit ‘robust pharmacodynamics’ and preliminary clinical benefit

Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765  to show  demonstrate ‘robust pharmacodymanics’

Oncalis license PI3K inhibitors from ChemDiv

Oncalis have entered in to an agreement to licence PI3K inhibitors, including ONC-201 from ChemDiv

Oncothyreon focus development on PI3K and HIF inhibitor

Oncothyreon have announced plans to prioritize resources on the clinical development of PI3K inhibitor  PX-478, HIF1 alpha inhibitor PX-866 and on process development and manufacturing of Stimuvax.

Piramed/Genentech publish data on PI3K inhibitor GDC-0941

Piramed/Genentech have published research leading to the development of lead compound GDC-0941

Semafores PI3K inhibitor SF1126 effective in vitro

Data presented at the Seventh International Congress on Targeted Therapies in Cancer show Semafore’s PI3 kinase (PI3K) inhibitor SF1126 to block both VEGF and Bv8 signaling in vitro

Semafore present data on PI3K inhibitors

Data presented at the Seventh International Congress on Targeted Therapies in Cancer detailed Semafore’s PI3K inhibitors including SF2523 and SF2506 which also inhibit mTOR, DNA-PK and PIM-1.

UCB describe series of PI3K inhibitors

UCB have published a paper detailing the optimization of multi-isoform PI3 kinase inhibitors

Novartis PI3K/mTOR inhibitor NVP-BEZ235 inhibit VEGF induced Angionesis/Cell proliferation

Novartis’ dual PI3K/mTOR inhibitor NVP-BEZ235 has been found to inhibit VEGF-induced cell proliferation in vitro and VEGF-induced angiogenesis in vivo. Activity is believed to be due to PI3K activity since RAD001 did not exhibit the same effects

IL-6/IL-8 expression inhibited by PI3K inhibitor LY-294002

Addition of PI3K inhibitor LY-294002 to S.mutans stimulated human odontoblast-like cells resulted in the reduced gene expression of IL-6 and IL-8